HGC019

HGC019 is a mRNA and Self-amplifying mRNA (saRNA) based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

HGC019 is a mRNA and Self-amplifying mRNA (saRNA) based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.

Economics

The company has received a funding of ₹250 crore (around US$33.5 million) from Government of India based on the clinical trials progress.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1321623291 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

8 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.